Treatment of Parkinson's Patients Using Levodopa Study
This is a two-part study. The first part of the study will test the effect of the study drug compared to placebo (a “sugar pill”). The second part of the study will collect safety and side-effect data in subjects who agree to continue to be treated with the study drug. All subjects continuing in the second part of the study receive active study drug. Participation in both parts of the study will last about 86 weeks (or approximately 1.5 years) and will include about 14 study visits. This study will include about 450 people ages 30-80 with a diagnosis of PD from about 80 different study sites in North America (U.S. and Canada), and Europe. Approximately six subjects are anticipated to be enrolled in this study at Rush University Medical Center.
In order to participate you must meet the following criteria:
- Have been diagnosed with having Parkinson's disease diagnosis.
- Have a minimum of three years since diagnosis.
- Meet Hoehn and Yahr PD stage.
- Have a good response to levodopa.
You will be excluded from the study if any of the following criteria apply to you:
- Have peviously participated in a tozadenant study.
- Are currently or have recently participated in another research study.
- Have secondary or atypical parkinsonism.
- Have undergone a neurosurgical intervention for PD.
This is a partial list of elgibility requirements.